PMID: 3746638Apr 1, 1986Paper

Ocular pharmacokinetic models of clonidine-3H hydrochloride

Journal of Pharmacokinetics and Biopharmaceutics
C H Chiang, R D Schoenwald

Abstract

A single topical instillation of clonidine-3H HCl solution (0.2%) was administered to the rabbit eye (30 microliter) in order to study the drug's ocular pharmacokinetics. Seven different tissues and plasma were excised and assayed for drug over 180 min. By 45-60 min pseudoequilibrium is reached for the cornea, iris/ciliary body, and aqueous humor. Thereafter, drug levels in these tissues decline in parallel. The data are fit separately to a physiological model and a classical diffusion model for which seven ocular tissue compartments and a plasma reservoir are constructed for each model. Clearance terms and distribution equilibrium coefficients are determined from the tissue level data and used as parameters in fitting the mass balance differential equations representing the physiological model. The model parameters can also be fit to a 0.4% single dose. In a separate experiment, a topical infusion technique was designed to provide a constant rate input to the cornea until an apparent steady state was reached in aqueous humor at 55 min. Aqueous humor levels were assayed for clonidine over the infusion and postinfusion periods. The physiological model parameters are fit to the topical infusion data and show good agreement betwee...Continue Reading

References

Jul 1, 1976·Journal of Pharmaceutical Sciences·A J Sedman, J G Wagner
Apr 1, 1979·Journal of Pharmaceutical Sciences·M C Makoid, J R Robinson
Jun 1, 1979·Journal of Pharmaceutical Sciences·V H Lee, J R Robinson
Mar 1, 1978·American Journal of Ophthalmology·M G DoaneC H Dohlman
Feb 1, 1977·Journal of Pharmaceutical Sciences·J M Conrad, J R Robinson
Sep 1, 1976·Journal of Pharmaceutical Sciences·T F Patton, J R Robinson
Feb 1, 1975·Journal of Pharmaceutical Sciences·T F Patton, J R Robinson
Jul 1, 1975·American Journal of Ophthalmology·R E HardbergerR Goodart
Jul 1, 1973·Journal of Pharmaceutical Sciences·S S ChraiJ R Robinson
Oct 1, 1973·Journal of Pharmaceutical Sciences·T J MikkelsonJ R Robinson
Nov 1, 1983·Journal of Pharmaceutical Sciences·R D Schoenwald, H S Huang
Oct 1, 1983·Journal of Pharmaceutical Sciences·L E Gerlowski, R K Jain
Dec 1, 1984·Journal of Pharmacokinetics and Biopharmaceutics·D D Tang-LiuR J Weinkam
Dec 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·S C MillerT F Patton

❮ Previous
Next ❯

Citations

Dec 8, 2000·Advanced Drug Delivery Reviews·K D Rittenhouse, G M Pollack
Apr 21, 1998·Journal of Pharmaceutical and Biomedical Analysis·K D RittenhouseG M Pollack
Dec 8, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·R D Schoenwald, J Zhu
Jan 3, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sheng-Fu HuangChiao-Hsi Chiang
Apr 14, 2010·Pharmaceutical Research·Heidi KidronArto Urtti
Aug 19, 2011·Journal of Pharmaceutical Sciences·Chandrasena R Pamulapati, Ronald D Schoenwald
Apr 3, 1999·Journal of Pharmaceutical Sciences·M R Prausnitz, J S Noonan
Sep 22, 2011·Journal of Pharmaceutical Sciences·Chandrasena R Pamulapati, Ronald D Schoenwald
Sep 24, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Wensheng ZhangAurélie Edwards
May 1, 1993·Survey of Ophthalmology·A Urtti, L Salminen
Jun 10, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ayumi MoriMitsuyoshi Azuma
Aug 1, 1992·Journal of Pharmacokinetics and Biopharmaceutics·C S RaoS L Laban
Feb 1, 1997·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·R D SchoenwaldC F Barfknecht
Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·C H ChiangJ L Chen
Nov 1, 1988·Biopharmaceutics & Drug Disposition·R D Schoenwald, D S Chien
Dec 12, 2019·Advances in Therapy·Marcelo Luís OcchiuttoAnastasios G Konstas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.